Answers are grounded in this paper and cite their sources.
Study investigates tissue factor's role in immune evasion and tisotumab vedotin efficacy in ovarian clear cell carcinoma, suggesting new therapeutic approaches.
Objective: Ovarian clear cell carcinoma (OCCC) characteristically overexpresses Tissue Factor (TF; F3), yet its biological significance and therapeutic implications remain unclear. We aimed to elucidate the impact of TF expression in OCCC and evaluate the antitumor efficacy of the anti-TF antibody-drug conjugate, tisotumab vedotin (TV), in vitro and in vivo models. Methods: We performed bulk RNA sequencing (RNA-seq) of 112 clinical OCCC cases to identify transcriptomic features of F3-high tumors. We then applied single-nucleus RNA-seq (snRNA-seq) to three F3-high and three F3-low cases to characterize tumor biology at the single-cell level. Based on these transcriptomic results, we focused on immune-related pathways and immune-checkpoint molecules, with emphasis on VTCN1 (B7-H4). Immunohistochemistry for TF and B7-H4 was performed on 57 OCCC specimens. Finally, we assessed TV activity in patient-derived OCCC spheroids and xenografts. Results: F3-high tumors exhibited lower immune scores with upregulation of MYC and cell cycle pathways, and suppression of inflammatory and immune pathways in bulk RNA-seq. Consistently, snRNA-seq showed similar trends in cancer cells, and immune fractions were significantly reduced in F3-high tumors, indicating an immunologically “cold” state. Notably, the immune-checkpoint molecule VTCN1 was highly expressed in F3-high tumors and positively correlated with F3 expression. Immunohistochemistry confirmed that B7-H4 was significantly overexpressed in TF-positive tumors, showing a positive correlation between TF and B7-H4 expression.TV activity correlated with TF abundance in vitro and induced marked growth inhibition in F3-high xenografts; residual tumors showed decreased TF and B7-H4 expression. Conclusions: TF-high OCCC shows a distinct gene expression pattern, particularly an immunologically cold subtype with B7-H4-mediated immune evasion. TV demonstrates TF-dependent activity, supporting TF as a therapeutic target, and providing rationale for TV-based monotherapy or combinations with immunotherapy in OCCC. Citation Format: Yutaro Mori, Ryo Tamura, Kotaro Takahashi, Kosuke Yoshihara. Tissue Factor expression is associated with B7-H4-mediated immune evasion in ovarian clear cell carcinoma and with response to tisotumab vedotin in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1761.
No takes yet. Share an insight, caveat, or question.
Mori et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: